CLRB Logo

Cellectar Biosciences, Inc. (CLRB) 

NASDAQ
Market Cap
$65.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
486 of 775
Rank in Industry
259 of 433

Largest Insider Buys in Sector

CLRB Stock Price History Chart

CLRB Stock Performance

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company …

Insider Activity of Cellectar Biosciences, Inc.

Over the last 12 months, insiders at Cellectar Biosciences, Inc. have bought $0 and sold $0 worth of Cellectar Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Cellectar Biosciences, Inc. have bought $139,443 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 25,000 shares for transaction amount of $26,000 was made by Swirsky Douglas J (director) on 2021‑09‑14.

List of Insider Buy and Sell Transactions, Cellectar Biosciences, Inc.

2021-09-14Purchasedirector
25,000
0.0418%
$1.04$26,000-43.80%
2021-09-03Purchasedirector
19,417
0.0328%
$1.04$20,244-42.72%
2021-03-04PurchasePresident and CEO
5,100
0.0103%
$1.70$8,659-43.68%
2020-12-28PurchaseChief Business Officer
29,630
0.0975%
$1.35$40,001-41.79%
2020-12-28PurchasePresident and CEO
37,037
0.1219%
$1.35$50,000-41.79%
2020-12-28PurchaseChief Financial Officer
7,407
0.0244%
$1.35$9,999-41.79%
2020-06-05PurchaseChief Business Officer
65,218
0.4749%
$1.15$74,675+26.32%
2020-06-05PurchasePresident and CEO
21,740
0.1583%
$1.15$24,892+26.32%
2020-06-05PurchaseChief Financial Officer
4,348
0.0317%
$1.15$4,978+26.32%
2020-06-04Purchasedirector
18,000
0.1236%
$1.08$19,438+25.88%
2019-02-28PurchaseChief Business Officer
100
0.0021%
$2.00$200+6.90%
2018-11-30PurchasePresident and CEO
1,000
0.0345%
$2.28$2,282-4.93%
2018-11-29Saledirector
992
0.0329%
$2.21$2,192-5.78%
2018-08-16PurchaseChief Business Officer
500
0.0149%
$2.71$1,355-22.38%
2018-03-13SaleChief Business Officer
13,000
0.0783%
$1.18$15,397-76.50%
2018-03-12SalePresident and CEO
34,000
0.2018%
$1.20$40,705-77.08%
2017-11-14Saledirector
5,214
0.0315%
$1.49$7,791-27.89%
2016-11-29Purchasedirector
333,333
2.668%
$1.49$496,666+6.45%
2016-10-31Sale
21,000
0.1919%
$2.03$42,609-9.19%
2016-04-21Purchase
7,516
0.1746%
$1.90$14,280+21.69%

Insider Historical Profitability

<0.0001%
MARXE AUSTIN W & GREENHOUSE DAVID M10 percent owner
1142368
2.768%
$1.5940
NEIS JOHNdirector
626103
1.5171%
$1.5931+9.32%
Hertzberg Richard
280000
0.6785%
$1.59121<0.0001%
BERNS PAUL Ldirector
117371
0.2844%
$1.5910+12.2%
Longcor JarrodChief Business Officer
102148
0.2475%
$1.5941<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Aigh Capital Management Llc$11.16M7.822.8M+46.45%+$3.54M6.38
Nantahala Capital Management Llc$7.46M5.231.87M+38.7%+$2.08M0.35
The Vanguard Group$4.74M3.321.19M+146.66%+$2.82M<0.0001
Barclays$1.35M0.94338,198New+$1.35M<0.01
Geode Capital Management$1.26M0.88316,084+358.96%+$983,984.21<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.